Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis.
Explore this paper's citation graph
Summary
This network meta-analysis suggested that lurasidone had similar efficacy and fewer metabolic effects than brexpiprazole in patients with acute schizophrenia.
- Type
- article
- Published
- 2018-04-26
- Cited by
- 17
- References
- 49
- Access
- Open access
- OpenAlex
- https://openalex.org/W2801936717
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13769615
Keywords
Lurasidone, Medicine, Schizophrenia (object-oriented programming), Meta-analysis, Internal medicine
References
- Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications
- Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
- Bayesian measures of model complexity and fit
- WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
- The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
- Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
- Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization
- Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
- Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
- Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
- Effect of degree of weight loss on health benefits.
- Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
- Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
- Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
- Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Cited by
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole: A Review in Schizophrenia
- Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
- Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
- Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
- Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
- New Antipsychotic Medications in the Last Decade
- Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review
- The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats
- Mechanism of Action and Uses of Lurasidone, A New Generation of Antipsychotics: A Review
- Third-Generation Antipsychotics and Lurasidone in The Treatment of Substance-Induced Psychoses: A Narrative Review
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
- NDT_A_282856 125..137
Related papers
- Effect of Pre-hospital Thrombolysis on Mortality in Patients with Myocardial Infarction: A Systematic Review and Meta-analysis
- PMH15 Budget IMPACT Analysis of Lurasidone VS Other Atypical Antipsychotics in Patients with Schizophrenia in China
- PMH26 Modeling Economic Consequences of Cardiometabolic Changes with Lurasidone Versus Other Atypical Antipsychotics in Schizophrenia
- EE398 Budget Impact Analysis of Lurasidone in the Treatment of Adult and Adolescent Patients With Schizophrenia in Spain
- F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
- ASSESSMENT OF THE MAXIMUM TOLERATED DOSE (MTD) OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA
- 149. Effect of Lurasidone on Quality of Life, Function, and Metabolic Parameters in Adolescent Patients With Schizophrenia: Results From a 6-Week, Double-Blind, Placebo-Controlled Study
- 6.16 Effect of Lurasidone on Neurocognitive Performance in Adolescents With Schizophrenia: Results of a Two-Year Open-Label Extension Study